All In Biotech

Drug Trial Radar · NCT06737731

A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors

A Phase I/II, Multicenter, Open-Label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1681 for Injection in Patients With Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Jan 21, 2025

Primary completion

Nov 2026

Study completion Jul 2027

Sponsor

Sponsor type
Industry
First posted
Dec 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-1681 for injection in patients with advanced solid tumors.

Conditions

  • Malignant Solid Tumors

Interventions

  • SHR-1681Drug

    SHR-1681 for Injection will be administrated per dose level in which the patients are assigned.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD)Time frame: 12 months.
  2. Maximum administered dose (MAD)Time frame: 12 months.
  3. Recommended Phase 2 dose (RP2D)Time frame: 12 months.
  4. Incidence and severity of adverse events (AEs)Time frame: Approximately 3 years.
  5. Incidence and severity of serious adverse events (SAEs)Time frame: Approximately 3 years.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai Dongfang Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.